Get started
Author

Ning Xu

ORCID: 0000-0003-1590-9359
Observed ORCID: 0000-0003-1590-9359
OpenAlex ID: A5102805482
Response to mRNA vaccination for COVID-19 among patients with multiple myeloma
2021 · Samuel D. Stampfer, Marissa-Skye Goldwater, et al. · Leukemia · 89
PDF
Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells
2019 · Haiming Chen, Mingjie Li, et al. · Leukemia Research · 75
JAK1/2 pathway inhibition suppresses M2 polarization and overcomes resistance of myeloma to lenalidomide by reducing TRIB1, MUC1, CD44, CXCL12, and CXCR4 expression
2019 · Haiming Chen, Mingjie Li, et al. · British Journal of Haematology · 64
PDF
Ruxolitinib reverses checkpoint inhibition by reducing programmed cell death ligand‐1 (PD‐L1) expression and increases anti‐tumour effects of T cells in multiple myeloma
2020 · Haiming Chen, Mingjie Li, et al. · British Journal of Haematology · 28
PDF
Baseline and Changes in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Patients with Relapsed/Refractory Multiple Myeloma Starting New Therapy
2021 · Sean Bujarski, Kyle Udd, et al. · Targeted Oncology · 20
Baseline serum B‐cell maturation antigen levels predict time to disease progression for patients with smoldering multiple myeloma
2021 · Sean Bujarski, Marissa‐Skye Goldwater, et al. · European Journal Of Haematology · 12
Third dose of an mRNA COVID-19 vaccine for patients with multiple myeloma
2022 · Marissa-Skye Goldwater, Samuel D. Stampfer, et al. · Clinical Infection in Practice · 10
PDF
The JAK Inhibitor Blocks PD-L1, PD-L2 and CD44 Expression in Multiple Myeloma (MM) and Sensitizes MM Cells to Lenalidomide and Steroids
2018 · Haiming Chen, Mingjie Li, et al. · Blood · 7
Loss of anti‐spike antibodies following mRNA vaccination for COVID ‐19 among patients with multiple myeloma
2023 · Samuel D. Stampfer, Sean Bujarski, et al. · Cancer Reports · 5
PDF
Baseline and Increases in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Relapsed/Refractory Multiple Myeloma Patients Undergoing New Treatments
2019 · Sean Bujarski, Kyle Udd, et al. · Blood · 5
The JAK1/2 inhibitor ruxolitinib downregulates the immune checkpoint protein B7H3 in multiple myeloma
2022 · Ning Xu, Erin Yu, et al. · Hematological Oncology · 4
Sars-Cov-2 Antibody Decay Monitoring in mRNA Vaccinated Multiple Myeloma Patients
2021 · Samuel D. Stampfer, Marissa-Skye Goldwater, et al. · Blood · 2
PDF
Ruxolitinib (RUX) reverses checkpoint inhibition by downregulating PD-L1 expression in both multiple myeloma (MM) tumor and stromal cells
2019 · Haiming Chen, Mingjie Li, et al. · Clinical Lymphoma Myeloma & Leukemia · 2
The inhibitory receptor PVRIG is dominantly expressed in the bone marrow of patients with multiple myeloma and its blockade enhances T-cell engager's immune activation
2024 · Masha Frenkel, Zoya Alteber, et al. · Experimental Hematology · 1
Ruxolitinib Enhances Anti-MM Function of Cytotoxic T-Cells By Upregulating IFNγ and Gzmb
2022 · Haiming Chen, Mingjie Li, et al. · Blood · 1
Evaluation of Repotrectinib's Anti-MM Effects in Combination with Bortezomib, Carfilzomib, Cyclophosphamide, and Dexamethasone in Vitro and Ex Vivo
2022 · Haiming Chen, Eric Souther, et al. · Blood · 1
Repotrectinib Alone and in Combination with Immunomodulatory Drugs Exhibits Potent Anti-Multiple Myeloma Activity
2022 · Haiming Chen, Eric Souther, et al. · Blood · 1
Dominant Expression of PVRIG and TIGIT Inhibitory Pathways in Bone Marrow of Multiple Myeloma Patients
2021 · Masha Frenkel, Zoya Alteber, et al. · Blood · 1
Changes in Serum B-Cell Maturation Antigen Levels Rapidly Predict Progression Free Survival among Multiple Myeloma Patients undergoing New Treatment
2019 · Sean Bujarski, Kyle Udd, et al. · Clinical Lymphoma Myeloma & Leukemia · 1
The JAK Inhibitor Pacritinib Suppresses the Checkpoint Proteins Pvrig and Tigit Expression on T Cells in Multiple Myeloma Patients
2022 · Ning Xu, Mingjie Li, et al. · Blood
Abstract 610: The expression of the PVRIG/TIGIT pathway is dominant in the bone marrow of patients with multiple myeloma
2022 · Masha Frenkel, Zoya Alteber, et al. · Cancer Research
Abstract 4195: Evaluation of the anti-myeloma effects of high and metronomic selinexor alone and in combination with duvelisib in vitro and in vivo
2022 · Haiming Chen, Stacy Behare, et al. · Cancer Research
Anti-Myeloma Effects of Panobinostat in Combination with Duvelisib
2021 · Haiming Chen, Mingjie Li, et al. · Blood
The JAK1/2 Inhibitor Ruxolitinib Downregulates CXCL12 Secretion from Bone Marrow Stromal Cells and M2 Macrophage Polarization in Multiple Myeloma
2019 · Haiming Chen, Mingjie Li, et al. · Blood
The JAK1/2 Inhibitor Ruxolitinib Downregulates the Immune Checkpoint Protein B7-H3 in Multiple Myeloma
2019 · Ning Xu, Nicole Ng, et al. · Blood
Works count: 26
Citation count: 329
H-index: 7
I10-index: 7
Year
Topic
Type